Transient HIF‐2α inhibition rescues MuSC proliferation and muscle repair under iron‐deficient conditions, highlighting HIF‐2α as a potential therapeutic target to counteract sarcopenia in aging and chronic diseases. The gene discussed is EPAS1; the disease is sarcopenia.